Outlook Therapeutics (OTLK) Set to Announce Earnings on Thursday

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) will be announcing its earnings results before the market opens on Thursday, May 16th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.20. On average, analysts expect Outlook Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Outlook Therapeutics Price Performance

Shares of OTLK traded down $0.15 during mid-day trading on Friday, hitting $7.58. 392,655 shares of the company's stock were exchanged, compared to its average volume of 245,950. Outlook Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $40.60. The business's 50 day moving average is $8.49 and its two-hundred day moving average is $8.57.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Chardan Capital raised shares of Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $60.00 price target for the company in a report on Thursday, February 15th. Brookline Capital Management upgraded Outlook Therapeutics from a "hold" rating to a "buy" rating and set a $31.40 price objective for the company in a research report on Thursday, January 25th. Guggenheim upgraded shares of Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $40.00 target price on the stock in a research report on Thursday, January 25th. HC Wainwright increased their price target on shares of Outlook Therapeutics to $30.00 and gave the company a "buy" rating in a report on Monday, March 25th. Finally, Capital One Financial reissued an "overweight" rating on shares of Outlook Therapeutics in a report on Friday, February 16th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.43.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.